Objective To investigate the effect and prognosis of Jianzhong Qiangxin Decoction combined with Trimetazidine in patients with chronic heart failure(CHF).Methods A total of 128 CHF patients admitted to Heshan Hospital of Chinese Medicine from June 2021 to June 2022 were selected as research objects,and they were divided into control group and ob-servation group according to random number table method,with 64 cases in each group.The control group was treated with Trimetazidine,and the observation group was treated with Jianzhong Qiangxin Decoction combined with Trimetazidine.The efficacy,heart function,6-min walking distance,traditional Chinese medicine syndrome score,incidence of adverse reac-tions and cumulative readmission rate were compared between the two groups.Results The total effective rate of the obser-vation group was higher than that of the control group,the difference was statistically significant(P＜0.05).After treatment,left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDD)in two groups were lower than those before treatment,left ventricular ejection fraction(LVEF)were higher than those before treatment,and LVESD and LVEDD in observation group were lower than those of control group,LVEF was higher than that of control group,with statistical significances(P＜0.05).The 6-min walking distance after treatment in the observation group was higher than that in the control group,and the traditional Chinese medicine syndrome score was lower than that in the control group,the dif-ferences were statistically significant(P＜0.05).After treatment,the quality of life scores of two groups were higher than those before treatment,and the quality of life score of observation group was higher than that of control group,the differences were statistically significant(P＜0.05).The cumulative readmission rate of the observation group was lower than that of the control group,and the difference was statistically significant(x 2=5.851,P=0.016).Conclusion Jianzhong Qiangxin Decoc-tion combined with Trimetazidine has significant clinical effect in CHF patients,and can effectively improve the cardiac function,prognosis and quality of life of patients,and reduce the incidence of readmission,which is worthy of clinical pro-motion and application.
维普
万方数据